Form 4: FibroBiologics Director Stacy Ann Coen Granted 22,000 Stock Options

FibroBiologics, Inc. Director Stacy Ann Coen was granted 22,000 stock options with an exercise price of $0.8725, vesting upon the earlier of the first anniversary of the grant date or the next annual meeting.

Summary

• Stacy Ann Coen, a Director of FibroBiologics, Inc. (FBLG), was granted 22,000 stock options on June 12, 2025.
• The stock options have an exercise price of $0.8725 per share.
• The options were granted at a price of $0, indicating they were part of compensation rather than a purchase.
• These options will vest in full upon the earlier of (i) the first anniversary of the grant date (June 12, 2026) or (ii) the date of the next annual meeting.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a Form 4 itself is a factual report, the grant of options to a director is generally viewed as a positive step for corporate governance, aligning management incentives with shareholder interests. There are no negative financial implications reported in this specific filing.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, as the options gain value if the company's stock price increases.
• Equity compensation is a common practice to attract and retain qualified board members.

Future Outlook

The granted stock options are subject to a vesting schedule, becoming fully exercisable upon the earlier of June 12, 2026, or the date of the next annual meeting, indicating a future milestone for the director's equity stake.

Industry Context

The grant of stock options to directors is a standard practice across various industries, particularly in publicly traded companies, as a form of non-cash compensation designed to incentivize long-term performance and align leadership interests with shareholder value.

Corporate Governance

Related Party Transactions

• The grant of 22,000 stock options to Stacy Ann Coen, a director of FibroBiologics, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from increased alignment of director's interests with company performance and shareholder value creation.

Next Steps

• The stock options will vest upon the earlier of June 12, 2026, or the date of the next annual meeting, at which point they will become fully exercisable.

Key Dates

Keywords

FibroBiologics, FBLG, Stock Option Grant, Insider Transaction, Director Compensation, Equity Compensation, Form 4, Beneficial Ownership